360iResearch
Talk to an analyst

Market research

Next Generation Sequencing

Report reference
MRR-4312A385A68A
Published
Geographic coverage
Global
Explore licenses

360iResearch introduction

Introduction to Next-Generation Sequencing

Next-generation sequencing (NGS) encompasses massively parallel methods for reading DNA and RNA, supporting applications in research, clinical diagnostics, reproductive health, oncology, infectious-disease surveillance, agriculture, and biopharmaceutical development. Its strategic importance reflects the ability to generate high-resolution genomic information while enabling broader sample analysis and increasingly integrated workflows. Adoption depends on analytical validity, laboratory capability, reimbursement, data governance, and the availability of skilled personnel.

Inside the research

Coverage at a glance

Selected branches from the published table of contents. Follow a chapter to explore its complete hierarchy.

  1. Chapter 7 Offering

    • Services
    • Consumables
    • Instruments & Workflow Systems
    • Software & Data Platforms
    View chapter

  2. Chapter 8 Sequencing Technology

    • Reversible-Terminator Sequencing by Synthesis
    • Combinatorial Probe-Anchor Synthesis
    • Semiconductor Sequencing
    • Nanopore Sequencing
    More in this chapter

  3. Chapter 9 Read Modality

    • Short Reads
    • Long Reads
    • Hybrid Read Workflows
    View chapter
Explore all chapters

Transformative Shifts Reshaping Sequencing Workflows

The landscape is shifting from standalone sequencing instruments toward integrated workflows that combine sample preparation, library construction, sequencing, bioinformatics, interpretation, and clinical or research reporting. Long-read technologies, single-cell analysis, spatial methods, liquid biopsy applications, and multiomics are expanding the questions that sequencing can address. At the same time, laboratories are prioritizing automation, standardized quality controls, interoperable data systems, and streamlined turnaround times. Regulatory scrutiny and the need to demonstrate clinical utility are increasingly shaping technology selection and adoption pathways.

Artificial Intelligence Across the Sequencing Lifecycle

Artificial intelligence is influencing NGS through base calling, signal interpretation, variant prioritization, quality assessment, image analysis, and clinical decision support. Machine-learning models can help identify complex patterns in large genomic datasets, improve workflow monitoring, and reduce manual review burdens when appropriately validated. However, effective deployment requires representative training data, transparent performance evaluation, cybersecurity controls, protection of sensitive genomic information, and human oversight. AI is therefore an enabling layer rather than a substitute for laboratory validation, clinical judgment, or robust governance.

Regional Insights: Divergent Adoption Conditions

North America benefits from substantial research infrastructure, advanced clinical laboratories, and established genomic medicine programs. Europe combines strong academic capabilities with varied reimbursement, regulatory, and data-sharing environments across countries. Asia-Pacific is supported by expanding biomedical research, population-scale initiatives, and growing laboratory capacity, although access and regulatory maturity differ widely. Latin America is developing sequencing applications in cancer, inherited disease, and public health while addressing infrastructure and funding constraints. The Middle East is strengthening precision-health programs and centralized healthcare capabilities, with implementation influenced by national strategies and data governance. Africa is applying NGS to infectious-disease surveillance, neglected conditions, and population genomics, while workforce development, logistics, and sustainable financing remain central priorities.

Group Insights Across Strategic Economic and Security Blocs

ASEAN markets present varied levels of laboratory maturity and are increasingly focused on infectious-disease monitoring, research collaboration, and workforce development. BRICS members contribute significant scientific capacity and population diversity, while their sequencing ecosystems differ in funding, regulation, infrastructure, and data-sharing practices. The European Union is shaped by coordinated research activity alongside national differences in healthcare implementation and genomic-data governance. G7 countries generally combine advanced research systems with strong expectations for evidence, privacy, and quality assurance. GCC states are emphasizing centralized precision-health infrastructure and national capability building. NATO members view genomic readiness, biosurveillance, and resilient health-data infrastructure as complementary elements of public-health and security planning.

Country Insights: Distinct National Priorities

Australia is advancing genomics through research networks, clinical translation, and population-health applications. Brazil is expanding sequencing for public health, biodiversity, and complex disease while managing geographic disparities. Canada emphasizes precision medicine, public research, and coordinated health-data practices. China is developing extensive research and clinical capabilities under a strong national biotechnology agenda. France, Germany, Italy, and Spain are strengthening genomic medicine, cancer applications, and laboratory networks within distinct national healthcare frameworks. India is applying NGS across infectious disease, inherited conditions, oncology, and agriculture while working to broaden access. Japan and South Korea combine sophisticated technology ecosystems with aging-population and clinical-translation priorities. Mexico is developing capacity for public-health surveillance and clinical applications. Russia maintains research and diagnostic activity shaped by domestic infrastructure and regulatory conditions. The United Kingdom continues to connect genomic research with national healthcare delivery and evidence-based implementation. The United States remains a major center for genomic research, clinical testing, biopharmaceutical innovation, and regulatory development.

Actionable Priorities for Industry Leaders

Leaders should align platform and workflow choices with clearly defined use cases, measurable analytical and clinical outcomes, and the operational realities of target laboratories. Investment priorities should include interoperability, automation, secure cloud or hybrid computing, validated bioinformatics, and workforce training. Partnerships with healthcare providers, public-health agencies, research institutions, and diagnostic laboratories can support evidence generation and responsible adoption. Organizations should also establish governance for genomic privacy, consent, data retention, algorithmic transparency, and incident response. Regional deployment plans should account for reimbursement, regulatory pathways, supply-chain resilience, local skills, and equitable access rather than relying on a single global operating model.

Research Methodology for the Executive Summary

This executive summary applies a structured, qualitative assessment of the next-generation sequencing landscape using the supplied market definition and the requested regional, group, and country coverage. The analysis synthesizes established technology, application, infrastructure, regulatory, workforce, and data-governance themes relevant to NGS adoption. It intentionally excludes market estimates, market sizing, market shares, forecasts, and company-specific comparisons. Conclusions are framed as evidence-based strategic interpretations and should be complemented by jurisdiction-specific regulatory, clinical, and reimbursement review before implementation decisions.

Conclusion: Building Reliable and Responsible Genomic Capability

NGS is becoming an enabling infrastructure for modern biomedical research, diagnostics, surveillance, and precision health rather than a narrowly defined laboratory technology. Progress will depend on the interaction of better sequencing modalities, integrated workflows, AI-assisted analysis, validated clinical pathways, and trusted data governance. Organizations that combine technical performance with operational resilience, regulatory readiness, workforce development, and equitable access will be better positioned to translate genomic information into durable scientific and healthcare value.

Research report

Table of contents

  1. 1.Preface
    1. 1.1Objectives of the Study
    2. 1.2Market Definition
    3. 1.3Market Segmentation & Coverage
    4. 1.4Years Considered for the Study
    5. 1.5Currency Considered for the Study
    6. 1.6Language Considered for the Study
    7. 1.7Key Stakeholders
  2. 2.Research Methodology
    1. 2.1Introduction
    2. 2.2Research Design
      1. 2.2.1Primary Research
      2. 2.2.2Secondary Research
    3. 2.3Research Framework
      1. 2.3.1Qualitative Analysis
      2. 2.3.2Quantitative Analysis
    4. 2.4Market Size Estimation
      1. 2.4.1Top-Down Approach
      2. 2.4.2Bottom-Up Approach
    5. 2.5Data Triangulation
    6. 2.6Research Outcomes
    7. 2.7Research Assumptions
    8. 2.8Research Limitations
  3. 3.Executive Summary
    1. 3.1Introduction
    2. 3.2CXO Perspective
    3. 3.3New Revenue Opportunities
    4. 3.4Next-Generation Business Models
    5. 3.5Industry Roadmap
  4. 4.Market Overview
    1. 4.1Introduction
    2. 4.2Industry Ecosystem & Value Chain Analysis
      1. 4.2.1Supply-Side Analysis
      2. 4.2.2Demand-Side Analysis
      3. 4.2.3Stakeholder Analysis
    3. 4.3Market Dynamics
      1. 4.3.1Key Drivers
      2. 4.3.2Key Restraints
      3. 4.3.3Key Opportunities
      4. 4.3.4Key Challenges
    4. 4.4Porter’s Five Forces Analysis
    5. 4.5PESTLE Analysis
    6. 4.6Market Outlook
      1. 4.6.1Near-Term Market Outlook (0–2 Years)
      2. 4.6.2Medium-Term Market Outlook (3–5 Years)
      3. 4.6.3Long-Term Market Outlook (5–10 Years)
    7. 4.7Go-to-Market Strategy
  5. 5.Market Insights
    1. 5.1Consumer Insights & End-User Perspective
    2. 5.2Consumer Experience Benchmarking
    3. 5.3Opportunity Mapping
    4. 5.4Distribution Channel Analysis
    5. 5.5Pricing Trend Analysis
    6. 5.6Regulatory Compliance & Standards Framework
    7. 5.7ESG & Sustainability Analysis
    8. 5.8Disruption & Risk Scenarios
    9. 5.9Return on Investment & Cost-Benefit Analysis
  6. 6.Cumulative Impact of Artificial Intelligence 2026
  7. 7.Next Generation Sequencing Market, by Offering
    1. 7.1Introduction
    2. 7.2Services
      1. 7.2.1NGS-Based Testing Services
      2. 7.2.2Library Preparation & Sequencing Services
      3. 7.2.3Bioinformatics & Data Analysis Services
      4. 7.2.4Support, Training & Qualification Services
      5. 7.2.5Workflow & Assay Development Services
    3. 7.3Consumables
      1. 7.3.1Sequencing Reagents & Run Consumables
      2. 7.3.2Library Preparation Kits
      3. 7.3.3Target Enrichment & Assay Panels
    4. 7.4Instruments & Workflow Systems
      1. 7.4.1Sequencing Systems
      2. 7.4.2Workflow Automation & Quality Control Systems
    5. 7.5Software & Data Platforms
      1. 7.5.1Secondary Analysis
      2. 7.5.2Tertiary Analysis & Reporting
      3. 7.5.3Data Management & Workflow Orchestration
      4. 7.5.4Run Control & Primary Analysis
  8. 8.Next Generation Sequencing Market, by Sequencing Technology
    1. 8.1Introduction
    2. 8.2Reversible-Terminator Sequencing by Synthesis
    3. 8.3Combinatorial Probe-Anchor Synthesis
    4. 8.4Semiconductor Sequencing
    5. 8.5Nanopore Sequencing
    6. 8.6Single-Molecule Real-Time Sequencing
    7. 8.7Flow-Based Sequencing by Synthesis
    8. 8.8Avidity Sequencing
    9. 8.9Antibody-Based Sequencing by Synthesis
    10. 8.10Sequencing by Expansion
  9. 9.Next Generation Sequencing Market, by Read Modality
    1. 9.1Introduction
    2. 9.2Short Reads
      1. 9.2.1Paired-End Short Reads
      2. 9.2.2Single-End Short Reads
    3. 9.3Long Reads
      1. 9.3.1Single-Pass Long Reads
      2. 9.3.2Consensus Long Reads
    4. 9.4Hybrid Read Workflows
  10. 10.Next Generation Sequencing Market, by Assay Type
    1. 10.1Introduction
    2. 10.2Genomic DNA Sequencing
      1. 10.2.1Targeted Gene & Region Sequencing
      2. 10.2.2Whole Genome Sequencing
      3. 10.2.3Whole Exome Sequencing
    3. 10.3Transcriptome Sequencing
      1. 10.3.1Whole Transcriptome & Messenger RNA Sequencing
      2. 10.3.2Targeted RNA Sequencing
      3. 10.3.3Small RNA Sequencing
    4. 10.4Metagenomic & Microbial Community Sequencing
      1. 10.4.1Shotgun Metagenomic Sequencing
      2. 10.4.2Marker Gene Amplicon Sequencing
      3. 10.4.3Metatranscriptomic Sequencing
    5. 10.5Epigenome & Chromatin Sequencing
      1. 10.5.1DNA Methylation Sequencing
      2. 10.5.2Protein-DNA Interaction Sequencing
      3. 10.5.3Chromatin Accessibility Sequencing
      4. 10.5.4Chromatin Conformation Sequencing
    6. 10.6Multiomic Sequencing
    7. 10.7Immune Repertoire Sequencing
    8. 10.8NGS-Readout Proteomic Assays
  11. 11.Next Generation Sequencing Market, by Assay Resolution
    1. 11.1Introduction
    2. 11.2Bulk & Pooled Sample Sequencing
    3. 11.3Single-Cell Sequencing
    4. 11.4Spatially Resolved Sequencing
    5. 11.5Single-Nucleus Sequencing
  12. 12.Next Generation Sequencing Market, by Application
    1. 12.1Introduction
    2. 12.2Clinical Diagnostics & Patient Management
      1. 12.2.1Oncology Testing
      2. 12.2.2Inherited & Rare Disease Testing
      3. 12.2.3Reproductive & Newborn Testing
      4. 12.2.4Infectious Disease Testing
      5. 12.2.5Pharmacogenomic Testing
      6. 12.2.6Immune & Transplant Testing
    3. 12.3Research & Discovery
      1. 12.3.1Genome & Variant Discovery
      2. 12.3.2Functional Genomics & Gene Regulation
      3. 12.3.3Microbiome Research
      4. 12.3.4Cell & Tissue Atlas Research
      5. 12.3.5Comparative & Evolutionary Genomics
    4. 12.4Biopharmaceutical Development
      1. 12.4.1Target & Biomarker Discovery
      2. 12.4.2Clinical Trial Stratification & Monitoring
      3. 12.4.3Cell & Gene Therapy Characterization
      4. 12.4.4Companion Diagnostic Development
      5. 12.4.5Biologic Safety & Quality Testing
    5. 12.5Agriculture & Animal Genomics
      1. 12.5.1Crop & Livestock Breeding
      2. 12.5.2Plant & Animal Health
    6. 12.6Population & Consumer Genomics
      1. 12.6.1Consumer Ancestry, Trait & Wellness Testing
      2. 12.6.2Population Genomics & Screening
    7. 12.7Public Health & Biosurveillance
      1. 12.7.1Pathogen Surveillance & Outbreak Response
      2. 12.7.2Antimicrobial Resistance Surveillance
    8. 12.8Food & Environmental Genomics
      1. 12.8.1Food Safety & Traceability
      2. 12.8.2Environmental & Biodiversity Monitoring
    9. 12.9Forensic & Identity Genomics
      1. 12.9.1Human Identification & Kinship
      2. 12.9.2Wildlife & Species Forensics
  13. 13.Next Generation Sequencing Market, by Buyer Type
    1. 13.1Introduction
    2. 13.2Healthcare & Diagnostic Organizations
      1. 13.2.1Clinical & Molecular Diagnostic Laboratories
      2. 13.2.2Hospitals & Health Systems
    3. 13.3Biopharmaceutical Organizations
      1. 13.3.1Pharmaceutical & Biotechnology Companies
      2. 13.3.2Contract Research Organizations
    4. 13.4Research Organizations
      1. 13.4.1Academic & Research Institutes
      2. 13.4.2Government Research Laboratories
    5. 13.5Genomics Service Providers
      1. 13.5.1Commercial Sequencing Service Providers
      2. 13.5.2Genome Centers & Core Facilities
    6. 13.6Public-Sector Testing Organizations
      1. 13.6.1Public Health Laboratories
      2. 13.6.2Forensic & Law-Enforcement Laboratories
    7. 13.7Life Science Tools & Diagnostic Developers
    8. 13.8Agriculture, Food & Environmental Organizations
      1. 13.8.1Agricultural & Animal Health Organizations
      2. 13.8.2Food Safety & Environmental Laboratories
    9. 13.9Individual Consumers
  14. 14.Next Generation Sequencing Market, by Delivery Model
    1. 14.1Introduction
    2. 14.2Customer-Managed Deployment
      1. 14.2.1Centralized Laboratory Deployment
      2. 14.2.2Customer-Managed Informatics
        1. 14.2.2.1On-Premises Informatics
        2. 14.2.2.2Customer-Managed Cloud Informatics
      3. 14.2.3Distributed & Point-of-Need Sequencing
    3. 14.3Provider-Hosted & Outsourced Delivery
      1. 14.3.1Outsourced Laboratory Services
        1. 14.3.1.1Sample-to-Report Testing Services
        2. 14.3.1.2Sequencing-to-Data Services
      2. 14.3.2Hosted Informatics
        1. 14.3.2.1Self-Service Vendor-Hosted Informatics
        2. 14.3.2.2Managed Bioinformatics Services
    4. 14.4Integrated Hybrid Deployment
  15. 15.Next Generation Sequencing Market, by Commercial Model
    1. 15.1Introduction
    2. 15.2Transactional Product Purchase
      1. 15.2.1Consumables & Kit Purchase
      2. 15.2.2Instrument & System Purchase
    3. 15.3Fee-for-Service
      1. 15.3.1Per-Sample & Per-Test Fees
      2. 15.3.2Project-Based Fees
    4. 15.4Subscription & Term Contract
      1. 15.4.1Service & Support Contract
      2. 15.4.2Software Subscription
    5. 15.5Usage-Based Software Access
      1. 15.5.1Pay-as-You-Go Usage
      2. 15.5.2Committed Usage Plan
    6. 15.6Lease & Placement
      1. 15.6.1Reagent-Commitment Placement
      2. 15.6.2Instrument Lease & Rental
    7. 15.7Development & Licensing
      1. 15.7.1Custom Development Agreement
      2. 15.7.2Technology & Intellectual Property License
  16. 16.Next Generation Sequencing Market, by Intended Use Status
    1. 16.1Introduction
    2. 16.2Research Use Only
    3. 16.3Regulator-Authorized In Vitro Diagnostic Use
    4. 16.4In-House Clinical Laboratory Use
    5. 16.5Investigational & Performance-Study Use
    6. 16.6Validated Non-Clinical Laboratory Use
  17. 17.Next Generation Sequencing Market, by Region
    1. 17.1Introduction
    2. 17.2Europe
    3. 17.3Asia-Pacific
    4. 17.4North America
    5. 17.5Latin America
    6. 17.6Middle East
    7. 17.7Africa
  18. 18.Next Generation Sequencing Market, by Group
    1. 18.1Introduction
    2. 18.2NATO
    3. 18.3G7
    4. 18.4European Union
    5. 18.5BRICS
    6. 18.6ASEAN
    7. 18.7GCC
  19. 19.Next Generation Sequencing Market, by Country
    1. 19.1Introduction
    2. 19.2United States
    3. 19.3China
    4. 19.4Germany
    5. 19.5Japan
    6. 19.6India
    7. 19.7United Kingdom
    8. 19.8France
    9. 19.9South Korea
    10. 19.10Canada
    11. 19.11Italy
    12. 19.12Australia
    13. 19.13Brazil
    14. 19.14Spain
    15. 19.15Russia
    16. 19.16Mexico
  20. 20.Competitive Landscape
    1. 20.1Market Share Analysis, 2025
    2. 20.2Market Concentration Analysis, 2025
      1. 20.2.1Concentration Ratio (CR)
      2. 20.2.2Herfindahl Hirschman Index (HHI)
    3. 20.3Recent Developments & Impact Analysis, 2025
    4. 20.4Product Portfolio Analysis, 2025
    5. 20.5Benchmarking Analysis, 2025
  21. 21.Company Profiles
    1. 21.1Illumina, Inc.
    2. 21.2Thermo Fisher Scientific Inc.
    3. 21.3Pacific Biosciences of California, Inc.
    4. 21.4Oxford Nanopore Technologies plc
    5. 21.5MGI Tech Co., Ltd.
    6. 21.6Element Biosciences, Inc.
    7. 21.7Ultima Genomics, Inc.
    8. 21.8QIAGEN N.V.
    9. 21.9Agilent Technologies, Inc.
    10. 21.10F. Hoffmann-La Roche Ltd
    11. 21.11Twist Bioscience Corporation
    12. 21.12New England Biolabs, Inc.
    13. 21.13Integrated DNA Technologies, Inc.
    14. 21.14Revvity, Inc.
    15. 21.15Takara Bio Inc.
    16. 21.16BGI Genomics Co., Ltd.
    17. 21.17Azenta Life Sciences
    18. 21.18Novogene Co., Ltd.
    19. 21.19Eurofins Genomics LLC
    20. 21.20Macrogen, Inc.
    21. 21.21GeneMind Biosciences Company Limited
    22. 21.22Annoroad Gene Technology (Beijing) Co., Ltd.
    23. 21.23Biomarker Technologies (BMKGENE)
    24. 21.24Qitan Tech
    25. 21.25Theragen Bio Co., Ltd.
    26. 21.26Welgene Biotech Co., Ltd.
    27. 21.27Genotypic Technology Pvt. Ltd.
    28. 21.28Australian Genome Research Facility Ltd
    29. 21.29CeGaT GmbH
    30. 21.30Microsynth AG
    31. 21.31GenomeScan B.V.
    32. 21.32NimaGen B.V.
    33. 21.33Inqaba Biotechnical Industries (Pty) Ltd
    34. 21.3410x Genomics, Inc.
    35. 21.35Singular Genomics Systems, Inc.
    36. 21.36Mission Bio
    37. 21.37Singleron Biotechnologies
    38. 21.38BioSkryb Genomics, Inc.
    39. 21.39Watchmaker Genomics
    40. 21.40Bruker Corporation
    41. 21.41Beckman Coulter, Inc.
    42. 21.42Volta Labs, Inc.
    43. 21.43INTEGRA Biosciences AG
    44. 21.44Daicel Arbor Biosciences
    45. 21.45Waters Corporation
    46. 21.46SOPHiA GENETICS SA
    47. 21.47DNAnexus, Inc.
    48. 21.48Sentieon, Inc.
    49. 21.49Velsera Inc.
  22. 22.Key Experts

Loading the sample request form…